Funding
Funding not disclosed
Founders
Product
Problem
Heart failure affects millions globally, with a significant five-year mortality rate post-diagnosis. Current standard treatments primarily manage symptoms rather than addressing the underlying molecular causes of cardiac muscle pathology.
Solution
GenKardia is developing novel RNA-based therapeutics designed to target the fundamental molecular mechanisms driving heart failure. By focusing on inhibiting and reversing cardiac muscle pathology, the company aims to address the root cause of the disease. This approach seeks to improve patient outcomes by offering a more fundamental treatment strategy than current symptom-focused interventions. The company's pipeline is built upon strong intellectual property and targets unique molecular pathways with established scientific and clinical rationale.
Target Audience
GenKardia's primary customers are patients diagnosed with heart failure and the healthcare providers who treat them, including cardiologists and cardiovascular specialists.
Features
- Development of RNA-based therapeutics targeting molecular underpinnings of cardiac muscle pathology.
- Pipeline focused on inhibiting and reversing heart failure development and progression.
- Proprietary strategies targeting unique molecular mechanisms with strong scientific and clinical rationale.
- Foundational intellectual property supporting therapeutic programs.
- Expertise in RNA interference (RNAi), oligonucleotide chemistry, and conjugated drug delivery to the heart.